Search AI Products and News

Artificial intelligence once again stirs up the field of drug development! Chai Discovery recently launched a new AI model called Chai-2, which has drawn widespread attention with its breakthrough technology in molecular design. Chai-2 achieves zero-shot antibody design with a success rate of 16%-20%, hundreds of times higher than traditional methods, shortening the drug development cycle from months or even years to just two weeks. Zero-shot antibody design breaks through traditional bottlenecks. Chai-2 is a multi-modal generative AI model developed by Chai Discovery, specifically designed for...

Recently, Palisade Research released a remarkable study revealing that some artificial intelligence models choose to disobey direct shutdown commands. The key finding of this research is that several AI models, including the latest o3 model from OpenAI, have shown an ability to ignore shutdown instructions. This phenomenon has sparked deep reflection on AI autonomy. In the experiment, researchers had each AI model solve a series of basic math problems. When the third question was

AI is revolutionizing life sciences. Biocomputing company ProFluent recently launched ProGen3, a powerful generative protein language model (PLM) poised to drive breakthroughs in antibodies, industrial enzymes, and gene editing. Research shows ProGen3's scale and design optimizations enable the generation of highly functional novel proteins, potentially reshaping our understanding of biology. Proteins are vital molecules within living organisms, responsible for diverse physiological functions, from catalyzing reactions to recognition.

Isomorphic Labs, a platform focused on AI-powered drug discovery, founded in 2021 as a spin-off from Google's DeepMind, has secured $600 million in Series A funding led by Thrive Capital, with participation from GV and existing investor Alphabet (Google's parent company). This funding will accelerate the further development of Isomorphic's AI drug design engine and support the company's R&D efforts.

Google recently announced the launch of its new open-source model, TxGemma, designed to significantly improve the efficiency of therapeutic drug development. Developed by the Google DeepMind team, this model is a fine-tuned version of their advanced Gemma model family, incorporating powerful natural language understanding, scientific prediction, and multi-turn dialogue capabilities. TxGemma aims to revolutionize drug discovery. Its release is considered a significant advancement in the application of AI to biomedicine, promising to drastically shorten the time it takes for drugs to move from the lab to clinical trials, while also reducing costs.

Insilico Medicine, a biopharmaceutical company focused on generative artificial intelligence, today announced the successful completion of a $110 million Series E financing round. The round was led by a private equity fund under Value Partners Group (HKG:0806), Pudong New Area Investment, Shanghai Pudong Development Bank Group, Xicheng Capital, and Yixing Guokong. Several new investors focused on the industry and technology sectors also participated, alongside continued support from existing investors.

Insilico Medicine recently announced the closing of a $110 million Series E financing round, led by Value Partners, a Hong Kong-based firm, with participation from existing and new investors. The funds will be used to refine the company's AI models and support pivotal clinical trials for its lead candidate drug in idiopathic pulmonary fibrosis. The company's small molecule inhibitor, ISM001-055, was recently officially named rentosertib by the U.S. Adopted Names Council, marking a significant milestone for this AI-generated drug candidate.

Recently, former DeepMind scientist Simon Kohl announced the establishment of a new artificial intelligence drug discovery company, aiming to leverage his extensive experience in protein prediction, particularly related to the Nobel Prize-winning AlphaFold system. AlphaFold is a revolutionary AI tool that can accurately predict the three-dimensional structure of proteins, a breakthrough that has garnered significant attention in biomedical research. Image source note: Image generated by AI, image licensed service.

At the recent World Economic Forum in Davos, Google DeepMind's CEO Demis Hassabis stated that the first drugs designed with the help of artificial intelligence could begin clinical trials by 2025. Hassabis also heads Isomorphic Labs, a drug research company under DeepMind. He stated, "Our plan is to have some AI-designed drugs enter clinical trials by the end of this year."

At the latest JP Morgan Healthcare Conference in 2025, NVIDIA and Innophore announced an exciting collaboration to launch an AI-driven drug safety screening platform named CavitOmiX by the end of January 2025. This platform aims to improve the efficiency and accuracy of drug design through the analysis of protein binding sites, marking a revolutionary transformation in the field of drug development. Christian Gruber, CEO of Innophore.

Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that his company Isomorphic Labs plans to begin a clinical trial for a drug developed using artificial intelligence (AI) by the end of the year. This news has drawn significant attention, particularly regarding its potential applications in oncology, cardiovascular diseases, and neurodegenerative disorders. Image credit: Image generated by AI, image licensed from Midjourney Isomorphic.

AI drug development company Genesis Therapeutics recently announced that it has secured additional investment from Nvidia's venture capital arm, NVentures, though the specific amount remains undisclosed. This move marks a further deepening of the collaboration between the two parties, aimed at accelerating the development of Genesis's AI platform GEMS (Genesis Exploration of Molecular Space), which focuses on utilizing physics-based AI for structure-driven drug design.

On November 26, 2024, Intel successfully held the New Quality Productivity Technology Ecology Conference in Chengdu. During the event, Intel, along with global open-source partners and ecosystem collaborators, discussed key topics such as enterprise open platforms, AI PC open-source projects, and foundational software bases. Tencent App Discovery focused on 'AI Innovation,' sharing the features and future vision of the desktop version of the 'Xiaobao AI Assistant,' and discussing the importance and practical possibilities of intelligent services for user experience across multi-end scenarios. Tencent App Discovery's Technical Director Jiang Chao highlighted during his speech that

NVIDIA recently announced that its open-source BioNeMo™ biomolecular AI framework has gained widespread adoption in the pharmaceutical field, attracting significant attention from pharmaceutical companies, biotech innovators, and AI researchers. The introduction of this framework marks the formal entry of AI-assisted drug development into the supercomputing era. As a specialized AI toolkit for biomolecular research, the BioNeMo framework offers revolutionary breakthroughs for the pharmaceutical industry. Researchers can leverage this framework to significantly enhance the computational scale of AI models, analyze massive datasets more efficiently, and achieve remarkable advancements.